Eric Murphy, Ph.D., co-founded Alterome Therapeutics Inc. with Dr. Ryan Corcoran from Mass General Hospital. He currently serves as both the Chief Executive Officer and Chief Scientific Officer. With over 20 years of drug discovery experience in small molecule oncology research across academia, CRO, biotech, and large pharma, Eric was previously co-Founder, CSO, and Board / SAB member at both Kinnate Biopharma Inc. (KNTE) and Fount Therapeutics LLC. Prior to that, Eric contributed to worldwide oncology research as the Global Head of Oncology R&D Strategy and External Innovations at Crown Biosciences prior to its acquisition by JSR. Eric and several Alterome team members have contributed to multiple approved oncology drugs and clinical stage oncology assets while at Novartis and Kinnate. Eric completed his postdoctoral fellowship at The Scripps Research Institute with Dr. David Cheresh and holds a BS in biochemistry from the University of California at Davis and a PhD in biological sciences from the University of California at Irvine. Eric enjoys volunteering his time as a dedicated oncology patient empowerment advocate, mentor to early entrepreneurs and budding researchers, and San Diego community steward through non-profit organizations such as Life Science Cares – San Diego. Onward!
Alterome is dedicated to relentlessly pushing the boundaries of cancer treatments to transform the lives of patients.
Our mission is to discover precise therapies and inspire hope for individuals affected by cancer.
Accelerating the next wave of targeted therapies
Our structure-guided drug discovery approach (“the KRAKEN”) enables the design of alteration-specific therapies to precisely target high-value, validated oncogenic drivers.
The alterome, consisting of all the disease driving alterations in genes, remains largely undrugged. Although technology and breakthroughs in drug development have created a new movement to control cancer through safer therapies, there remain too few treatment options for cancers with genomically-defined drivers. We are pursuing this next bar in targeted therapy with a combination of chemistry, biology, pharmacology, and genomics. Challenge accepted!
Board of Directors
Scientific Advisory Board
Benjamin Cravatt, Ph.D.
Professor & Gilula Chair of Chemical Biology, The Scripps Research Institute
Our people make the difference! If you share our vision to transform the lives of cancer patients, join our Movement.